Detalhe da pesquisa
1.
Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement.
Bioorg Med Chem
; 100: 117618, 2024 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38309201
2.
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Nature
; 492(7427): 108-12, 2012 Dec 06.
Artigo
Inglês
| MEDLINE | ID: mdl-23051747